FDA to End Emergency Use Authorization For Invivyd's Covid-19 Prevention Shot
By Dean Seal
Invivyd said regulators are ending emergency use authorization for its Covid-19 prevention medication, Pemgarda.
The Food and Drug Administration sent Invivyd a notice of termination, with the designation set to end June 29 of next year.
The Department of Health and Human Services is winding down emergency authorizations related to Covid-19 for drugs and biological products, as well as medical devices, after concluding that the circumstances for those authorizations had abated.
Pemgarda is an investigational antibody authorized in March 2024 for prevention of Covid-19 in adults and adolescents with moderate-to-severe immune compromise due to certain medical conditions or their use of immunosuppressive medications.
Marc Elia, Invivyd's board chairman, said the end of the formal emergency for Covid-19 products was "in many ways overdue," as the designation isn't the same as a product approval.
"We feel as though a full approval of Pemgarda is well-warranted at this time by the totality of demonstrated safety and efficacy data," he said.
Invivyd is in active dialogue with FDA on next steps.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
July 06, 2026 12:13 ET (16:13 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States